The Top Line

Deep dive: Biopharma layoffs in Q1

5 snips
Apr 12, 2024
Industry analyst Gabrielle Masson and expert Max Bayer discuss the surge in biopharma layoffs in Q1 2024, analyzing the reasons behind this trend. They also highlight positive industry developments amidst the challenges faced by companies. The podcast explores investment dynamics, job market realities, and the shift towards cautious expansion in the biopharma sector.
Ask episode
Chapters
Transcript
Episode notes